logo
Plus   Neg
Share
Email

Amgen: ABP 798 Shows Clinical Equivalence To Rituxan In Clinical Study

Amgen (AMGN) and Allergan plc (AGN) said a clinical study demonstrated clinical equivalence of ABP 798 to Rituxan in patients with CD20-positive B-cell non-Hodgkin's lymphoma. In the study, the overall response rate by week 28 was within the prespecified margin for ABP 798.

Safety and immunogenicity of ABP 798, a biosimilar candidate, were comparable to Rituxan. The comparative clinical study was the second of two studies to support regulatory submissions for ABP 798.

In 2011, Amgen and Allergan plc formed a collaboration to develop and commercialize oncology antibody biosimilar medicines.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Millennials and Generation Zs, or people aged between 18 to 34 year, pay more for car repairs, according to a new survey. The average American spent $1,986 over the past five years on vehicle repairs and maintenance, according to a survey by Ally Financial conducted by Harris Poll. However, among... Gap Inc.'s (GPS) Old Navy brand announced plans to open 800 new stores as part of its upcoming split from its parent company. "We'll almost double our fleet to 2,000 stores in North America, predominantly in under-served small markets," Old Navy CEO Sonia Syngal said. The company said the plan was... Google has launched a new website called 'Recover Together,' a resource intended to help people recover from addiction or substance use disorder. The new service was launched by the search giant in recognition of the National Recovery Month in September. Google noted that more than 23 million Americans are recovering from addiction, while 20 million are still struggling to seek treatment.
Follow RTT